| 注册
首页|期刊导航|外科理论与实践|分化型甲状腺癌术后促甲状腺激素抑制治疗的共识和争议

分化型甲状腺癌术后促甲状腺激素抑制治疗的共识和争议

刘杰 先柯瑶

外科理论与实践2023,Vol.28Issue(6):507-511,5.
外科理论与实践2023,Vol.28Issue(6):507-511,5.DOI:10.16139/j.1007-9610.2023.06.04

分化型甲状腺癌术后促甲状腺激素抑制治疗的共识和争议

Consensus and controversy in postoperative thyroid stimulating hormone suppression therapy for differentiated thyroid carcinoma

刘杰 1先柯瑶1

作者信息

  • 1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院,北京协和医学院肿瘤医院 头颈外科,北京 100021
  • 折叠

摘要

Abstract

Differentiated thyroid carcinoma(DTC)is the most common thyroid carcinoma,with a generally favorable prognosis for most patients.At present,Surgery,131I and thyroid stimulating hormone(TSH)suppression are the main therapeutic means among which,TSH suppression therapy plays an important role in the postoperative management of DTC patients,which has the effect of decreasing the risk of recurrence,slowing down the progression of the disease,and improving long-term survival.However,excessive TSH suppression can increase the risk of adverse events in the cardiovascular and skeletal systems.Currently,there is ongoing debate regarding the optimal target range for serum TSH suppression in patients of all types.In clinical practice,it is important to carefully balance the benefits and potential risks of TSH suppression,and to personalize the target range for serum TSH based on dynamic assessments during patient follow-up.This article aimed to discuss the intensity,benefits,and risks of TSH suppression after surgery for DTC patients,as well as the current controversies about this topic.

关键词

分化型甲状腺癌/术后管理/促甲状腺激素抑制治疗

Key words

Differentiated thyroid carcinoma/Postoperative management/Thyroid stimulating hormone suppression therapy

分类

医药卫生

引用本文复制引用

刘杰,先柯瑶..分化型甲状腺癌术后促甲状腺激素抑制治疗的共识和争议[J].外科理论与实践,2023,28(6):507-511,5.

外科理论与实践

OACSTPCD

1007-9610

访问量0
|
下载量0
段落导航相关论文